Ligand (LGND) Breakout! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout!

LGND 199.20

+0.1%

Nov 21 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: John O'Neill who wrote (17791)	3/23/1998 1:50:00 PM
From: Henry Niman	Read Replies (1) of 32384

JO, I don't think that the "problem" with Evista in mice will translate into a human problem. There was no indication in the human clinicals and an intermediate found in mice was not found in humans. Evista approval gives LGND are companion drug for treating and/or preventing breast cancer and its likely that Targretin (or a second generation rexinoid) would also have osteoporosis applications (which will be enhanced by the rexinoid). I'm not sure what PFE's diabetic drug is. If it's a TZD, it will probably be enhanced by Targretin (or a second generation TZD).

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next